J&J Exec On COVID-19 Vaccine: Moving At High Speed But No Safety Compromises
'Different Way Of Working'
J&J executive emphasizes that fast-tracked development of COVID-19 vaccines does not come with any corners cut around safety. Indian partner Biological E also outlines the complexities in manufacturing and believes that the candidates from J&J, AstraZeneca and others will be more suitable in profile and price terms to contain the pandemic globally.
You may also be interested in...
Reliance Life Sciences, part of India’s largest private sector enterprise with a growing engagement in healthcare, is progressing an early-stage COVID-19 vaccine. A top executive underscores the potential to manufacture at scale and provide the protein-based candidate at a competitive price.
Operation Warp Speed officials eye the Moderna vaccine and upcoming one-shot Janssen product to widen the immunization campaign’s reach, but more products also could bring more problems.
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.